Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 years and older
• People who are able to give written consent on their own behalf
• People who have had a needle core biopsy that confirmed a breast cancer diagnosis
• People with a single breast tumor that is no larger than 15 mm at its widest point, and is either naturally located at least 5 mm away from the skin and chest wall, or can be moved that far away using a saline or local anaesthetic injection
• People whose tumor has no more than 10 mm of calcium deposits, and those deposits are contained within the tumor itself
• People whose tumor can be clearly seen on ultrasound or mammogram imaging, without the edges being hidden by surrounding tissue or image interference
• People whose tumor is clearly visible on MRI
• People with dense breast tissue on a mammogram may be considered, as long as a clear marker is visible at the tumor site
• People whose tumor has less than 25% intraductal growth (a measure of how the cancer has spread within the breast ducts), as shown by core biopsy
• People without serious ongoing illnesses that affect life expectancy
• People who weigh 136 kg (300 lbs) or less
• People who agree to follow their doctor's recommended radiation or additional drug therapy after the procedure

Who may not be able to join:

• People under 18 years of age
• People who are pregnant or breastfeeding
• People whose tumor cannot be clearly seen on ultrasound or mammogram imaging
• People who have had an allergic reaction to gadolinium-based contrast dye, or who have moderate to severe kidney disease (confirm specific kidney function threshold with trial site)
• People who cannot have an MRI scan for any reason, such as having a pacemaker or certain metal implants (confirm with trial site)
• People with a history of severe asthma
• People whose tumor is larger than 15 mm at its widest point
• People whose calcium deposits extend beyond the tumor, making the combined size larger than 15 mm
• People with advanced-stage breast cancer
• People whose tumor is a specific type not included in this trial, such as lobular neoplasm, cancer that has spread to the breast from elsewhere, sarcoma, Phyllodes tumor, or Paget's disease
• People whose biopsy shows only a very early and limited form of cancer called DCIS with microinvasion
• People whose tumor has more than 25% intraductal growth, as shown by core biopsy
• People who are known to carry a BRCA gene mutation
• People whose cancer tests negative for oestrogen receptors, progesterone receptors, and HER2 (known as triple-negative breast cancer)
• People who are unable to lie flat on their front or back for one hour
• People who are currently taking part in another clinical study involving a treatment, device, or drug that could interfere with this trial
• People who have not had a HER2 test performed according to the relevant professional guidelines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.